Filings & corporate actions
79 results filed
CSVNext results · Q2 FY27
Expected 27 Oct 2026 – 5 Nov 2026
Estimate: filed 27–36 days after quarter end, last 5 times
Dividend
₹13.00 per share · last 5 Jun 2026
2026
- 23 JulresultsResults · Q1 FY27 · consolidated and standalone+1.3%NSE
- 21 JulshareholdingShareholding · 30 Jun 2026-0.6%NSE
- 5 JundividendDividend · ₹13.00 per share+0.2%
- 13 MayresultsResults · Q4 FY26 · consolidated and standalone+8.2%NSE
- 21 AprshareholdingShareholding · 31 Mar 2026+0.2%NSE
- 23 JanresultsResults · Q3 FY26 · consolidated and standalone-0.2%NSE
- 21 JanshareholdingShareholding · 31 Dec 2025-0.6%NSE
Reaction to results · all yearsrose on day 0 in 31 of 77 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 23 Jul 2026 | +1.3% | +5.8% | +2.8% | 2.0× |
| Q4 FY26 | 13 May 2026 | +8.2% | +5.6% | +4.7% | 4.6× |
| Q3 FY26 | 23 Jan 2026 | -0.2% | -0.3% | +0.9% | 1.9× |
| Q2 FY26 | 30 Oct 2025 | -2.5% | -1.9% | -1.1% | 2.3× |
| Q1 FY26 | 25 Jul 2025 | +2.6% | -1.1% | +3.1% | 2.5× |
| Q4 FY25 | 13 May 2025 | -1.7% | -2.5% | +0.1% | 2.1× |
| Q3 FY25 | 29 Jan 2025 | +0.2% | +2.0% | +3.0% | 2.8× |
| Q2 FY25 | 29 Oct 2024 | -4.0% | +7.9% | +3.8% | 2.8× |
| Q1 FY25 | 26 Jul 2024 | -1.3% | -3.8% | +1.5% | 2.4× |
| Q4 FY24 | 11 May 2024 | +5.6% | +4.8% | +14.5% | 4.5× |
| Q3 FY24 | 22 Jan 2024 | +7.0% | +2.6% | +10.0% | 4.9× |
| Q2 FY24 | 28 Oct 2023 | +1.6% | +2.5% | +1.5% | 1.7× |
| Q1 FY24 | 26 Jul 2023 | +9.6% | +9.1% | +13.2% | 12.2× |
| Q4 FY23 | 12 May 2023 | -1.6% | -1.3% | +2.4% | 2.2× |
| Q3 FY23 | 25 Jan 2023 | +1.2% | -1.3% | -7.1% | 2.6× |
| Q2 FY23 | 5 Nov 2022 | -1.3% | -2.4% | -3.2% | 1.4× |
| Q4 FY22 | 11 May 2022 | -0.6% | +1.3% | +4.9% | 1.2× |
| Q3 FY22 | 25 Jan 2022 | +2.4% | +5.2% | -1.1% | 4.0× |
| Q2 FY22 | 27 Oct 2021 | -3.3% | -1.3% | +4.6% | 0.9× |
| Q1 FY22 | 6 Aug 2021 | -3.6% | -5.4% | +0.5% | 4.1× |
| Q4 FY21 | 14 May 2021 | -2.5% | +3.0% | +8.0% | 1.5× |
| Q3 FY21 | 29 Jan 2021 | -2.4% | +2.6% | -4.4% | 3.1× |
| Q2 FY21 | 7 Nov 2020 | -3.4% | -6.0% | -3.5% | 3.0× |
| Q1 FY21 | 8 Aug 2020 | +9.2% | +5.9% | -1.6% | 7.5× |
| Q4 FY20 | 16 May 2020 | +5.3% | +10.1% | +11.8% | 2.5× |
| Q3 FY20 | 6 Feb 2020 | -1.8% | -0.9% | -2.9% | 2.9× |
| Q2 FY20 | 8 Nov 2019 | -2.0% | -2.4% | -5.1% | 1.0× |
| Q1 FY20 | 8 Aug 2019 | -2.9% | -8.2% | -9.0% | 3.3× |
| Q4 FY19 | 23 May 2019 | +2.1% | +1.6% | -0.3% | 2.4× |
| Q3 FY19 | 12 Feb 2019 | 0.0% | -0.7% | -1.9% | 0.9× |
| Q2 FY19 | 19 Nov 2018 | -1.4% | -2.5% | -0.7% | 0.4× |
| Q1 FY19 | 24 Aug 2018 | -1.0% | +0.6% | +0.6% | 0.7× |
| Q4 FY18 | 25 May 2018 | +0.5% | -3.0% | +13.9% | 0.7× |
| Q3 FY18 | 16 Mar 2018 | +0.1% | -3.1% | +4.5% | 1.1× |
| Q2 FY18 | 8 Nov 2017 | -1.3% | -4.8% | -4.7% | 0.9× |
| Q1 FY18 | 22 Aug 2017 | -0.4% | +0.8% | +1.4% | 0.6× |
| Q4 FY17 | 26 May 2017 | -3.0% | +5.2% | +7.4% | 6.2× |
| Q3 FY17 | 11 Feb 2017 | +0.5% | +2.2% | +3.5% | 0.8× |
| Q2 FY17 | 11 Nov 2016 | +0.8% | +0.5% | +5.6% | 1.2× |
| Q1 FY17 | 4 Oct 2016 | -1.0% | -1.8% | -8.9% | 0.5× |
| Q4 FY16 | 25 May 2016 | -4.9% | -5.9% | -2.3% | 12.6× |
| Q3 FY16 | 11 Feb 2016 | -2.3% | -3.0% | -0.6% | 1.3× |
| Q2 FY16 | 5 Nov 2015 | 0.0% | -4.9% | -2.3% | 0.9× |
| Q1 FY16 | 16 Aug 2015 | -4.9% | -14.0% | -10.7% | 5.3× |
| Q4 FY15 | 29 May 2015 | +1.8% | -5.5% | -6.1% | 1.3× |
| Q3 FY15 | 19 Feb 2015 | -1.0% | -1.8% | +2.5% | 0.7× |
| Q2 FY15 | 17 Nov 2014 | -0.9% | +1.8% | +1.6% | 1.2× |
| Q1 FY15 | 18 Aug 2014 | +5.0% | +13.1% | +38.1% | 3.0× |
| Q4 FY14 | 29 May 2014 | +3.2% | +6.4% | +17.3% | 1.3× |
| Q3 FY14 | 18 Feb 2014 | +0.3% | +0.9% | +4.3% | 0.5× |
| Q2 FY14 | 18 Nov 2013 | -0.4% | -4.0% | -3.6% | 1.1× |
| Q1 FY14 | 12 Aug 2013 | +1.5% | -1.8% | +5.9% | 2.8× |
| Q4 FY13 | 14 Jun 2013 | +0.6% | +0.6% | +7.9% | 0.5× |
| Q3 FY13 | 6 Feb 2013 | -2.7% | -5.8% | -4.6% | 3.8× |
| Q2 FY13 | 5 Nov 2012 | +4.4% | +3.7% | +8.3% | 7.1× |
| Q1 FY13 | 31 Jul 2012 | +4.5% | +3.7% | +11.2% | 6.3× |
| Q4 FY12 | 11 May 2012 | -2.3% | -3.1% | -5.3% | 1.0× |
| Q3 FY12 | 13 Feb 2012 | -6.1% | -7.0% | -9.4% | 4.7× |
| Q2 FY12 | 14 Nov 2011 | +6.5% | +9.9% | +13.3% | 5.4× |
| Q1 FY12 | 5 Aug 2011 | -1.3% | -7.4% | -5.4% | 1.1× |
| Q4 FY11 | 5 May 2011 | +0.6% | +1.5% | +6.9% | 2.3× |
| Q3 FY11 | 4 Feb 2011 | -3.0% | -3.5% | -5.2% | 1.9× |
| Q2 FY11 | 11 Nov 2010 | -0.7% | +4.9% | +7.1% | 2.4× |
| Q1 FY11 | 13 Aug 2010 | -3.4% | +0.8% | -1.4% | 4.8× |
| Q4 FY10 | 7 May 2010 | -6.7% | -7.9% | -5.8% | 3.2× |
| Q3 FY10 | 28 Jan 2010 | -0.2% | -2.6% | -0.5% | 1.6× |
| Q2 FY10 | 28 Oct 2009 | -3.6% | -3.0% | +6.5% | 1.5× |
| Q1 FY10 | 29 Jul 2009 | -3.2% | -2.8% | -7.6% | 1.9× |
| Q4 FY09 | 24 Apr 2009 | +1.5% | -5.2% | -7.6% | 3.4× |
| Q3 FY09 | 22 Jan 2009 | +7.6% | +11.1% | +7.6% | 3.2× |
| Q2 FY09 | 22 Oct 2008 | -1.6% | -3.5% | +2.4% | 0.8× |
| Q1 FY09 | 18 Jul 2008 | +5.6% | +3.7% | +9.0% | 1.5× |
| Q4 FY08 | 25 Apr 2008 | -4.3% | -3.5% | -7.6% | 1.7× |
| Q3 FY08 | 24 Jan 2008 | +6.4% | +13.9% | +15.3% | 0.5× |
| Q2 FY08 | 24 Oct 2007 | -5.2% | -10.5% | -6.8% | 1.6× |
| Q1 FY08 | 20 Jul 2007 | -4.7% | -6.0% | -11.6% | 3.1× |
| Q4 FY07 | 26 Apr 2007 | -14.3% | -16.5% | -13.8% | 22.3× |
| Average | -0.2% | -0.4% | +1.6% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+2.3%
Profit YoY-39.2%
Interest cost YoY-1.3%
Revenue QoQ+8.8%
Profit QoQ+44.8%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +4.1% | +6.1% | — | +6.9% | +8.4% | +8.1% |
| Profit | -12.0% | +2.4% | — | +5.8% | +12.9% | +12.3% |
Key data
CSVOpen1,335.00
Day range1,323.20 – 1,344.90
52-week range1,165.70 – 1,673.00
From 52w high-19.9%
RSI (14)35.0
ATR (14)25.74
Volume5.76L
Avg volume (20D)9.91L
Rel volume0.58×
Volatility (1Y)20.8%
Turnover₹77.2Cr
SMA 50 / 2001,412.64 / 1,379.03
Delivery percentage
Latest · 6 Oct 202657.9%
20-day avg56.8%
1-year avg55.8%
Percentile (own history)73rd
Range6.9–81.1%
Sessions1,731
Over the last 20 sessions CIPLA settled 56.8% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 55.8%. The latest session ranks higher than 73% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +0.35% | -3.14% | -3.91% | -7.69% | +12.40% | -10.62% |
Valuation
CSVMarket cap₹1.08L Cr
P/E (TTM)32.3
EPS (TTM)41.54
Shares outstanding80.78Cr
Listed8 Feb 1995
Ownership
CSVPromoter29.21%
Promoter Δ QoQ0.00 pp
Public70.79%
FII20.21%
DII34.63%
Pledged0.00%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 7,589.4 | 7,074.5 | 6,541.2 | 7,119.3 |
| YoY chg | +7.6% | +0.0% | -2.8% | +2.3% |
| Net profit (₹ Cr) | 1,353.4 | 674.3 | 542.5 | 785.6 |
| YoY chg | +3.7% | -57.2% | -55.3% | -39.2% |
| Net margin | 17.8% | 9.5% | 8.3% | 11.0% |
| EPS | 16.72 | 8.36 | 6.86 | 9.76 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 29.21% · public 70.79%2021-092026-06
- Promoter
- Public and others
- Promoter
- 29.21%
- Public
- 70.79%
- Promoter change
- 0.00 pp
- Filed
- 21 Jul 2026
- FII
- 20.21%
- DII
- 34.63%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 6,678.2 | 6,603.8 | 6,163.2 | 6,693.9 | 7,051.0 | 7,073.0 | 6,729.7 | 6,957.5 | 7,589.4 | 7,074.5 | 6,541.2 | 7,119.3 | |
| Other income | 176.3 | 184.6 | 249.3 | 160.2 | 190.6 | 221.6 | 289.5 | 258.6 | 269.0 | 206.3 | 148.2 | 210.9 | |
| Total income | 6,854.5 | 6,788.4 | 6,412.6 | 6,854.1 | 7,241.6 | 7,294.6 | 7,019.2 | 7,216.0 | 7,858.4 | 7,280.8 | 6,689.4 | 7,330.2 | |
| Total expenses | 5,260.2 | 5,119.8 | 5,153.3 | 5,242.8 | 5,452.6 | 5,378.5 | 5,514.9 | 5,446.1 | 6,004.9 | 6,111.8 | 5,982.3 | 6,248.3 | |
| └ Finance costs | 25.8 | 30.1 | 17.6 | 18.0 | 15.4 | 14.6 | 14.0 | 14.1 | 13.2 | 14.0 | 13.1 | 17.0 | |
| └ Depreciation | 290.0 | 233.4 | 288.3 | 246.7 | 271.7 | 279.8 | 308.7 | 252.7 | 297.0 | 278.4 | 382.9 | 304.2 | |
| Profit before tax | 1,594.2 | 1,473.8 | 1,259.3 | 1,611.4 | 1,789.1 | 1,916.1 | 1,504.3 | 1,769.9 | 1,853.5 | 893.1 | 707.1 | 1,081.9 | |
| Tax expense | 438.4 | 405.3 | 324.9 | 435.1 | 483.0 | 332.4 | 279.3 | 477.9 | 500.5 | 218.6 | 157.0 | 294.8 | |
| Net profit | 1,155.4 | 1,068.4 | 931.9 | 1,175.5 | 1,305.0 | 1,574.6 | 1,214.1 | 1,291.6 | 1,353.4 | 674.3 | 542.5 | 785.6 | |
| EPS | 14.01 | 13.08 | 11.63 | 14.58 | 16.13 | 19.45 | 15.13 | 16.07 | 16.73 | 8.37 | 6.87 | 9.77 | |
| Net margin | 17.30% | 16.18% | 15.12% | 17.56% | 18.51% | 22.26% | 18.04% | 18.56% | 17.83% | 9.53% | 8.29% | 11.03% | |
| PBT margin | 23.87% | 22.32% | 20.43% | 24.07% | 25.37% | 27.09% | 22.35% | 25.44% | 24.42% | 12.62% | 10.81% | 15.20% | |
| Tax rate | 27.50% | 27.50% | 25.80% | 27.00% | 27.00% | 17.35% | 18.57% | 27.00% | 27.00% | 24.47% | 22.20% | 27.25% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 23 Jul 2026.
CIPLA at a glance
- CIPLA closed at ₹1,340.2 on 6 Oct 2026, +0.35% on the day, -10.6% over one year, 19.9% below its 52-week high of ₹1,673.
- Delivery was 57.9% of traded quantity on 6 Oct 2026, the 73rd percentile of its own 1,731 sessions with a reading (20-session average 56.8%, 1-year average 55.8%).
- Market capitalisation is ₹1.08 lakh crore at a trailing P/E of 32.3 (trailing EPS ₹41.54).
- Q1 FY27 results (consolidated, filed 23 Jul 2026): revenue ₹7,119 crore (+2.3% year on year), net profit ₹786 crore (-39.2%); the price moved +1.3% on the first session after.
- Promoters held 29.21% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 27 Oct 2026 and 5 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE059A01026
SeriesEQ
Listed8 Feb 1995
History from2 Jan 1995
Sessions7,853
Turnover rank#233
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE